CFDB - Cystic Fibrosis DataBase

primary studies congress abstract

Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: patient-reported outcomes in a Phase 3, randomised, controlled trial (EVOLVE)


Pneumologie (Stuttgart, Germany), 2019, 73(SUPPPL. 1)

Keywords: Adult; Aged; CFTR Modulators; Genetic Predisposition to Disease; pharmacological_intervention; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; VX-445; Symdeko; Symkevi;